Viatris aktuell WKN: A2QAME ISIN: US92556V1061 Kürzel: VTRS Forum: Aktien User: DonauPirat

Capital Allocation The Company is reaffirming its commitment to prioritizing returning capital to shareholders in 2025 as previously stated. Year-to-date, the Company returned more than $450 million of capital to shareholders, including over $300 million in share repurchases and ~$143 million in dividends paid. The Company expects $500 million to $650 million in total share repurchases in 2025 and expects to be opportunistic with cash available throughout the year. From a business development perspective, the Company expects to continue to pursue regional licensing and partnership opportunities with immediate revenue contribution that leverage its unique commercial and R&D infrastructure and capabilities.

Additional Highlights The Company received positive results from the Phase 3 open-label, long-term extension study for EFFEXOR® required for approval in Japan and the Company filed applications to the Ministry of Health, Labor and Welfare for approval of EFFEXOR SR Capsules (venlafaxine hydrochloride), a serotonin-noradrenaline reuptake inhibitor to treat adults with generalized anxiety disorder, an indication for which no other treatment option is currently approved in Japan. The Company announced positive top-line results from two pivotal Phase 3 studies of its novel fast-acting formulation of meloxicam (MR-107A-02) for the treatment of moderate-to-severe acute pain. The Phase 3 program consisted of two randomized, double-blind, placebo-(double-dummy) and active-controlled trials – one following herniorrhaphy surgery and one following bunionectomy surgery. In both Phase 3 studies, all primary and secondary endpoints were met and MR-107A-02 demonstrated statistically significant and clinically meaningful results. The Company is targeting to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) by the end of 2025. The Company announced positive results of its Phase 3 study evaluating the contraceptive efficacy and safety of investigational XULANE LO™ low dose weekly dermal patch with 150 mcg norelgestromin and 17.5 mcg ethinyl estradiol per day in women of childbearing potential. In this study, XULANE LO demonstrated a favorable efficacy and safety profile with no new safety concerns identified, as well as a potential best-in-class patch performance profile. The Company plans to submit an NDA to the FDA in the second half of 2025.

Quarterly Financial Highlights First quarter 2025 total revenues were $3.3 billion, down 11% on a reported basis and down 2% on a divestiture-adjusted operational basis compared to first quarter 2024, primarily driven by the negative Indore Impact. Excluding the Indore Impact, total revenues would have increased 2% on a divestiture-adjusted operational basis compared to first quarter 2024. Brands net sales reflect the expansion of the Company's portfolio in Emerging Markets, and strong growth in Greater China and Developed Markets. Generics net sales reflect the expected negative Indore Impact, partially offset by growth in certain complex products in North America, strong performance across key European markets, and volume growth in JANZ. The Company generated approximately $67 million in new product revenues in the quarter and continues to expect to deliver approximately $450 million to $550 million in new product revenues in 2025. First quarter 2025 U.S. GAAP net loss was $(3.0) billion compared to U.S. GAAP net earnings of $114 million in the first quarter of 2024, and U.S. GAAP diluted EPS was a loss of $(2.55) per share in Q1 2025 compared to a gain of $0.09 per share in Q1 2024, in each case primarily driven by a non-cash goodwill impairment charge of $2.9 billion in the current quarter. See "Goodwill Impairment" for more information. First quarter 2025 adjusted EBITDA was $923 million, down 23% on a reported basis and down 12% on a divestiture-adjusted operational basis compared to the first quarter of 2024, and adjusted EPS was $0.50 per share in Q1 2025, down 25% on a reported basis and down 14% on a divestiture-adjusted operational basis compared to Q1 2024, both primarily driven by the negative Indore Impact. The Company generated U.S. GAAP net cash provided by operating activities of $535 million, and free cash flow of $493 million, including $43 million in transaction-related costs.

Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook A) Delivers Total Revenues in Line With Expectations Demonstrating Strength of the Base Business B) Makes Significant Pipeline Progress With Three Positive Phase 3 Data Readouts C) Returns More Than $450 Million in Capital to Shareholders Year-to-Date and Reaffirms 2025 Capital Allocation Priorities

Heute gibts die Quartalszahlen! Teva hat gestern abgeräumt. Was hat Viatris in den Karten?

Milliardenmark-Kuchen dieses Eylea und Patente laufen aus! Muss Viatris doch dabei sein, oder?

Hat Viatris eigentlich ein Eylea Generika/Biosimilar in der Pipleline? Bei Teva läuft wohl eine Studie gut. Wirkstoff ist Aflibercept.

Selbst Vodafone erholt sich

6,59 €

während PFIZER aufdreht!

*speachless* lausige 6,66 €

hier geht echt garnichts voran im Kurs

aber der schwache Dollar bringt doch nur dann was, wenn Umsätze im Ausland mit Fremdwährung generiert werden und dadurch der Gewinn in Dollar steigt?

Viatris hat nur Forschung in USA. Die Produktion ist in billigeren Ländern wie Indien etc Das machen alle Pharma Unternehmen. Indien ist der weltweit größte OEM Fabrikstandort für alle möglichen Pharma Rohstoffe. DT hat noch nicht verstanden dass bevor er die Zulassungsbehörde halbiert hat. Auch vorher hat die Zulassung einer Fabrik in USA mehrere Jahre bei extrem hohen Kosten. Das US Basis Gesundheitssystem für Arme und Ältere verkraftet diese Kosten nicht. DT lebt in einer anderen Welt. Es war auch bei uns in der Presse daß fast alle Pillen in Indien oder ähnlich billigen Ländern produziert werden. Das gilt erst Recht für Generika. Wall Street macht aktuell ein Thema daraus und shortet. Die Pharma Konzerne müssen jetzt beweisen dass sie profitabel damit fertig werden. Ich glaube ja.

Ja , das habe ich gelernt. War zu 7.50$ ausgestiegen und habe zu 6% niedrigerem $ Kurs bei 7.05 zurück gekauft. Im Verlust kann man das ohne steuerliche Nachteile machen.